In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Viralytics Limited

http://www.viralytics.com/

Latest From Viralytics Limited

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

Financing StartUps and SMEs

Transgene Downplays Impact Of Pexa-Vec Phase III Cancer Trial Failure

A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.

Clinical Trials Research & Development

AZ Targets Viral Oncolytics With Transgene Development Deal

AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.

Research & Development Deals

Merck Strengthening Vaccine Capabilities By Acquiring Troubled Immune Design

Recently battered by clinical setbacks, Immune Design has a co-development partnership with Merck around Keytruda and Merck’s Perlmutter is a former board member. Merck would pay roughly $300m to acquire the company and its immune system-boosting technologies.

Deals ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register